Hormonal
Sarcolemmal localization of C18:0 ceramide and specific sphingomyelin species is inversely related to insulin sensitivity in human skeletal muscle, whereas sarcolemmal 1,2-DAGs are not significantly related.
Focus on improving insulin sensitivity through exercise and metabolic health rather than just obsessing over total body fat or muscle fat content. The location and type of lipids matter more than the total amount. Endurance training appears to alter lipid localization in a way that preserves insulin sensitivity despite higher total lipid levels.
Sarcolemmal ceramides were inversely related to insulin sensitivity, with a significant relationship found for the C18:0 species. Sarcolemmal sphingomyelins were also inversely related to insulin sensitivity... Sarcolemmal 1,2-DAGs were not significantly related to insulin sensitivity.
Why this rating
Human study with rigorous measurement (hyperinsulinemic-euglycemic clamp) and specific lipidomics, though cross-sectional.
Source
Intracellular localization of diacylglycerols and sphingolipids influences insulin sensitivity and mitochondrial function in human skeletal muscle
Leigh Perreault et al. · JCI Insight · 2018
DOI 10.1172/jci.insight.96805
More from this paper
- Mitochondrial/ER localization of 1,2-DAGs is positively related to insulin sensitivity, whereas mitochondrial ceramide accumulation is inversely related.Good
- Sarcolemmal ceramide accumulation decreases mitochondrial state 3 respiration and increases proton leak, thereby impairing mitochondrial function.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →